RailTel lands ₹12.85 Crore MGIMS IT deal through 2032

TECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
RailTel lands ₹12.85 Crore MGIMS IT deal through 2032
Overview

RailTel Corporation of India has received a ₹12.85 crore contract from Mahatma Gandhi Institute Of Medical Sciences for a comprehensive IT project. The multi-year deal, running until March 31, 2032, includes a Hospital Information Management System (HIMS), fire safety, and campus management systems. This expands RailTel's work in healthcare IT and secures income over several years.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

RailTel Lands ₹12.85 Crore MGIMS IT Deal Through 2032

RailTel Corporation of India has secured a significant IT project valued at ₹12.85 crore from the Mahatma Gandhi Institute Of Medical Sciences (MGIMS). The contract, which excludes taxes, has a long execution period stretching to March 31, 2032, representing nearly six years of work.

Project Scope and Systems

The comprehensive IT solution includes customization, integration, deployment, and ongoing maintenance. Key systems to be implemented are a Hospital Information Management System (HIMS), a Hospital Fire Safety Management System, and a broader Campus Management System covering student activities and accounts.

Strategic Importance

This award strengthens RailTel's presence in the healthcare IT sector. It demonstrates the company's ability to deliver comprehensive digital solutions for medical institutions. The extended execution period offers RailTel substantial income for the coming years.

Background: RailTel's Healthcare IT Wins

RailTel, a Navratna PSU, has been increasing its focus on healthcare IT. Recently, it secured a ₹56.71 crore contract for a Hospital Management Information System (HMIS) across seven medical colleges in Assam. It also won a ₹13.04 crore HMIS project from the Mumbai Port Authority with a five-year execution term. In September 2021, the company secured an HMIS order from Indian Railways worth ₹42.38 crore. These projects highlight RailTel's growing expertise in digitizing health operations for public sector entities.

What This Means for RailTel

This new project adds a significant item to RailTel's order book, boosting its future earnings potential. It reinforces the company's strategy to expand its ICT services into specialized areas like healthcare and education. The long contract duration suggests a stable income stream and deeper integration with the client.

Key Risks

RailTel, as a Government Company, has faced penalties from NSE and BSE for failing to meet SEBI's board composition rules, often due to delays in director appointments by the Ministry of Railways. Additionally, a GST penalty of ₹49.24 lakh was imposed by the CGST office in Itanagar, which the company plans to contest. The project's long timeline until March 31, 2032, could present challenges in long-term project management and revenue booking.

Peer Comparison

Telecommunications Consultants India Limited (TCIL), another government-owned enterprise, also handles IT and telecom projects for public sector clients. While TCIL's work is broad, including e-governance, RailTel is concentrating more on specific sectors like healthcare IT, as seen with this MGIMS order.

Investor Focus

Investors will be watching for the project's timely start and progress against milestones. The company's effectiveness in managing long-duration projects will be key to earning the full revenue. Future announcements of similar IT and HMIS projects in healthcare and education will signal the company's growth momentum.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.